TEM
Tempus AI, Inc. Class A Common Stock
About: Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Employees: 2,300
0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
276% more first-time investments, than exits
New positions opened: 79 | Existing positions closed: 21
214% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 14
62% more call options, than puts
Call options by funds: $75.7M | Put options by funds: $46.8M
59% more funds holding
Funds holding: 96 [Q3] → 153 (+57) [Q4]
17% more funds holding in top 10
Funds holding in top 10: 6 [Q3] → 7 (+1) [Q4]
8.72% more ownership
Funds ownership: 25.2% [Q3] → 33.92% (+8.72%) [Q4]
18% less capital invested
Capital invested by funds: $2.12B [Q3] → $1.74B (-$375M) [Q4]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$52
24%
downside
Avg. target
$62
9%
downside
High target
$74
9%
upside
6 analyst ratings
5 positive
83%
1 neutral
17%
0 negative
0%
TD Cowen Dan Brennan 41% 1-year accuracy 12 / 29 met price target | 9%upside $74 | Buy Reinstated | 5 Feb 2025 |
Loop Capital Mark Schappel 76% 1-year accuracy 26 / 34 met price target | 24%downside $52 | Buy Maintained | 14 Jan 2025 |
Needham Ryan MacDonald 56% 1-year accuracy 38 / 68 met price target | 18%downside $56 | Buy Reiterated | 14 Jan 2025 |
B of A Securities Michael Ryskin 75% 1-year accuracy 3 / 4 met price target | 21%downside $54 | Neutral Maintained | 13 Dec 2024 |
Wolfe Research Doug Schenkel 20% 1-year accuracy 1 / 5 met price target | 12%downside $60 | Outperform Initiated | 13 Dec 2024 |
Financial journalist opinion
Based on 29 articles about TEM published over the past 30 days
Positive
Seeking Alpha
15 hours ago
3 Biotech/Healthcare Names Under $10 I Am Buying Now
Today, I am highlighting three biotech/healthcare stocks that currently trade under $10 a share after some recent weakness. ! am slowly accumulating each of these names on these dips both straight equity purchases and covered call orders. All have had some recent positive despite the action in the shares and have good longer-term prospects.
Neutral
Finbold
1 day ago
5 stocks Congress is buying in 2025
The stock trading activities of US Congress members continue to draw attention, with disclosures under the STOCK Act providing insight into their investment strategies. So, in this piece, we bring you the top 5 stocks Congress is buying in 2025.
Neutral
Business Wire
2 days ago
Tempus to Present at TD Cowen's 45th Annual Health Care Conference
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will present at the TD Cowen 45th Annual Health Care Conference on March 3-5, 2025 in Boston, MA. Tempus' Chief Financial Officer, Jim Rogers, will participate in a fireside discussion at the conference on Monday, March 3. A live webcast of the conversation will be available here. About Tempus Tempus is a technology company advancing precision.
Neutral
Business Wire
3 days ago
Ares Management Upsizes Tempus Debt Facilities to $560 Million
NEW YORK--(BUSINESS WIRE)--Ares Management Corporation (NYSE: ARES) (“Ares”), a leading global alternative investment manager, announced today that Ares Credit funds served as the administrative agent on $300 million in incremental debt financing for Tempus AI, Inc. (NASDAQ: TEM) (“Tempus”), a technology company leading the adoption of AI to advance precision medicine and patient care. The financing is intended to support Tempus' previously announced acquisition of Ambry Genetics (“Ambry”), whi.
Positive
Seeking Alpha
3 days ago
Tempus AI Is A Buy On Dips In The AI-Driven Healthcare Sector
TEM basically mixes genomic and clinical data with AI. This is at the core of their new offerings for precision diagnostics and personalized treatments. Recently, they've made some interesting moves like acquiring Ambry Genetics, launching the Olivia health app, and collaborating with IFLI. TEM also has other innovative assets like xT CDx, xH tests, and enhanced Tempus One that I think position it perfectly for agentic AI diagnostics.
Neutral
Business Wire
3 days ago
Tempus to Participate in the Morgan Stanley Technology, Media and Telecom Conference
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, will participate in the Morgan Stanley Technology, Media & Telecom Conference on Monday, March 3-6, 2025, held in San Francisco, CA. Tempus Founder and CEO, Eric Lefkofsky, will participate in a fireside discussion at the conference on Monday, March 3, 2025. A live webcast of the conversation will be available here. About Tempus Tempus is a.
Positive
The Motley Fool
3 days ago
25 Top AI Stocks That Could Boost Your Portfolio
The artificial intelligence (AI) revolution is reshaping the global economy at an unprecedented pace, with innovations emerging across every sector from healthcare to transportation. As companies race to integrate AI capabilities into products and services, investors are keenly searching for opportunities to capitalize on this technological transformation.
Positive
MarketBeat
4 days ago
Conflicting Signals: Tempus AI's Stock Market Rally
Tempus AI NASDAQ: TEM is a leader in precision medicine and artificial intelligence (AI) in the healthcare sector. Tempus AI's stock price has seen an increase, with gains of over 160% in the last month and almost 150% year-to-date, causing investors to surge in interest.
Neutral
Business Wire
1 week ago
Tempus Announces Collaboration with IFLI Aimed at Supporting Development of Targeted Therapies for Follicular Lymphoma
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a new collaboration with the Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL). The collaboration aims to develop and make available a real-world multimodal, deidentifie.
Positive
The Motley Fool
1 week ago
Think It's Too Late to Buy Tempus AI Stock? Here's the Biggest Reason Why There's Still Time.
Refusing to slow down since the start of the new year, shares of Tempus AI (TEM 3.75%) have skyrocketed nearly 99% since Jan. 1. In light of the artificial intelligence (AI) stock's strong performance so far this year, prospective investors may fear there's not much share price growth potential left for Tempus, an innovator in applying AI solutions to the healthcare industry.
Charts implemented using Lightweight Charts™